ALK and anaplastic large cell lymphoma: Thus it was clearly demonstrate that a prolonged response can be achieved with anti-PD1 therapy in patients with NPM-ALK+ ALCL refractory to chemotherapy and ALK inhibitors [76] or after allogeneic hematopoietic stem cell transplant [77] and in patients with relapses [78].